Skip to content
DataLookout
Menu

NCT01223248

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 41 versions: 32 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 2026 to Oct 2027
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Publications: details revised at 2 of 2 entries
  2. Notable Primary and study completion dates: Oct 2025 to Oct 2026v40
  3. Notable Primary and study completion dates: Oct 2024 to Oct 2025v39
  4. Notable Primary and study completion dates: Oct 2023 to Oct 2024v37
  5. Notable Primary and study completion dates: Oct 2022 to Oct 2023v36
Show 26 earlier versionsHide 26 earlier versions
  1. Notable Primary and study completion dates: Oct 2021 to Oct 2022v35
  2. Notable Primary and study completion dates: Oct 2020 to Oct 2021v34
  3. Notable Primary and study completion dates: Oct 2019 to Oct 2020v32
  4. Notable Primary and study completion dates: Oct 2018 to Oct 2019v31
  5. Notable Primary and study completion dates: Oct 2017 to Oct 2018
    • Site details revised at 1 of 4 sites
    v29
  6. Notable Primary and study completion dates: Oct 2016 to Oct 2017
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 300 to confirmed 220
    • Site details revised at 4 of 4 sites
    v28
  7. Minor Site details revised at 1 of 4 sitesv27
  8. Minor Site details revised at 2 of 4 sitesv26
  9. Minor Site details revised at 1 of 4 sitesv25
  10. Notable Trial status: Suspended to Recruiting
    • Enrollment target: 200 to 300
    • Site details revised at 4 of 4 sites
    v23
  11. Stopped Trial status: Recruiting to Suspended
    • Primary and study completion dates: Oct 2015 to Oct 2016
    • Site details revised at 4 of 4 sites
    v22
  12. Minor Study sites revised (4)v21
  13. Minor Site details revised at 1 of 4 sitesv19
  14. Notable Primary and study completion dates: Oct 2014 to Oct 2015
    • Site details revised at 1 of 4 sites
    v18
  15. Notable Eligibility criteria expanded, about 1 word
    • Study sites: 3 to 4
    • Collaborators: 2 to 3
    v17
  16. Notable Trial status: Suspended to Recruiting
    • Site details revised at 3 of 3 sites
    v16
  17. Stopped Trial status: Recruiting to Suspended
    • Site details revised at 3 of 3 sites
    v15
  18. Notable Primary and study completion dates: Oct 2013 to Oct 2014
    • Site details revised at 1 of 3 sites
    v13
  19. Notable Eligibility criteria shortened, about 21 wordsv12
  20. Notable Enrollment target: 100 to 200
    • Eligibility criteria expanded, about 1 word
    • Study sites: 2 to 3
    • Collaborators: 1 to 2
    v10
  21. Notable Primary and study completion dates: Oct 2012 to Oct 2013
    • Eligibility criteria revised
    • Secondary endpoints: 3 to 4
    v7
  22. Notable Eligibility criteria expanded, about 4 wordsv6
  23. Notable Eligibility criteria expanded, about 35 words
    • Secondary endpoints: 2 to 3
    v5
  24. Notable Eligibility criteria expanded, about 49 wordsv4
  25. Notable Eligibility criteria expanded, about 14 wordsv3
  26. Minor Study sites: 1 to 2v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To compare the loco-regional control rates of two established hypo-fractionated radiation treatment regimens
Timeframe: 2 years

Secondary (4)

To compare toxicity outcomes
To compare patterns of failure between these two cohorts.
To look at changes in SUV uptake as a measure of tumor response.
changes in tumor perfusion

Arms and interventions

stereotactic IGIMRT using a single dose of 24 GyExperimental

This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease

stereotactic IGIMRT 27 Gy in 3 fractionsExperimental

This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease

Radiation: IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions

Sites

4 sites in 3 countries

United States 2, Italy 1, Portugal 1